CN105229024A - 肾病综合征及相关病状的治疗方法 - Google Patents

肾病综合征及相关病状的治疗方法 Download PDF

Info

Publication number
CN105229024A
CN105229024A CN201480028465.6A CN201480028465A CN105229024A CN 105229024 A CN105229024 A CN 105229024A CN 201480028465 A CN201480028465 A CN 201480028465A CN 105229024 A CN105229024 A CN 105229024A
Authority
CN
China
Prior art keywords
seq
angptl4
sequence
positions
proteinuria
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201480028465.6A
Other languages
English (en)
Chinese (zh)
Inventor
苏曼特·S·丘格
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Suman S Chugh
Original Assignee
UAB Research Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US13/841,240 external-priority patent/US9139629B2/en
Application filed by UAB Research Foundation filed Critical UAB Research Foundation
Publication of CN105229024A publication Critical patent/CN105229024A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/515—Angiogenesic factors; Angiogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Vascular Medicine (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Saccharide Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
CN201480028465.6A 2013-03-15 2014-03-15 肾病综合征及相关病状的治疗方法 Pending CN105229024A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US13/841,240 2013-03-15
US13/841,240 US9139629B2 (en) 2010-06-05 2013-03-15 Methods for treatment of nephrotic syndrome and related conditions
PCT/US2014/030009 WO2014145275A1 (en) 2013-03-15 2014-03-15 Methods for treatment of nephrotic syndrome and related conditions

Publications (1)

Publication Number Publication Date
CN105229024A true CN105229024A (zh) 2016-01-06

Family

ID=51537930

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201480028465.6A Pending CN105229024A (zh) 2013-03-15 2014-03-15 肾病综合征及相关病状的治疗方法

Country Status (8)

Country Link
EP (1) EP2970416B1 (https=)
JP (1) JP2016516726A (https=)
KR (1) KR102221041B1 (https=)
CN (1) CN105229024A (https=)
AU (1) AU2014233219B2 (https=)
CA (3) CA2906982C (https=)
NZ (1) NZ712935A (https=)
WO (1) WO2014145275A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112689762A (zh) * 2018-06-01 2021-04-20 美国控股实验室公司 用于lc-ms/ms蛋白质组学基因分型的方法和系统

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101706296B1 (ko) 2015-12-21 2017-02-13 주식회사 브레인온 기억력, 학습력, 인지력 향상용 조성물
US20180201645A1 (en) * 2015-12-21 2018-07-19 Brainon Inc. Composition for improving memory, learning ability, and cognitive ability
CN112292125B (zh) * 2018-06-22 2023-10-31 西奈克制药有限公司 蛋白尿的治疗

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101080419A (zh) * 2004-07-20 2007-11-28 健泰科生物技术公司 利用血管生成素样4蛋白的组合物和方法
WO2011153525A2 (en) * 2010-06-05 2011-12-08 The Uab Research Foundation Methods for treatment of nephrotic syndrome and related conditions

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9475850B2 (en) * 2010-06-05 2016-10-25 The Uab Research Foundation Methods for treatment of nephrotic syndrome and related conditions
US20110301103A1 (en) * 2010-06-05 2011-12-08 Chugh Sumant S Methods of Treatment

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101080419A (zh) * 2004-07-20 2007-11-28 健泰科生物技术公司 利用血管生成素样4蛋白的组合物和方法
WO2011153525A2 (en) * 2010-06-05 2011-12-08 The Uab Research Foundation Methods for treatment of nephrotic syndrome and related conditions

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
WU YIN: "Genetic Variation in ANGPTL4 Provides Insights into Protein Processing and Function", 《THE JOURNAL OF BIOLOGICAL CHEMISTRY》 *
郑敬民: "管生成素样蛋白2在糖尿病肾病小鼠肾组织中的表达定位", 《医学研究生学报》 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112689762A (zh) * 2018-06-01 2021-04-20 美国控股实验室公司 用于lc-ms/ms蛋白质组学基因分型的方法和系统
US12163963B2 (en) 2018-06-01 2024-12-10 Laboratory Corporation Of America Holdings Methods and systems for LC-MS/MS proteomic genotyping

Also Published As

Publication number Publication date
KR20150140686A (ko) 2015-12-16
CA3152699C (en) 2023-09-05
CA2906982A1 (en) 2014-09-18
EP2970416A1 (en) 2016-01-20
WO2014145275A1 (en) 2014-09-18
CA3207108A1 (en) 2014-09-18
AU2014233219B2 (en) 2018-02-22
NZ712935A (en) 2020-03-27
HK1220213A1 (en) 2017-04-28
AU2014233219A1 (en) 2015-10-08
KR102221041B1 (ko) 2021-02-25
CA3152699A1 (en) 2014-09-18
JP2016516726A (ja) 2016-06-09
EP2970416B1 (en) 2023-11-22
EP2970416A4 (en) 2017-02-22
EP2970416C0 (en) 2023-11-22
CA2906982C (en) 2022-05-31

Similar Documents

Publication Publication Date Title
EP2558115B1 (en) Methods for treating metabolic disorders using fgf
EP2970422B1 (en) Il-22 polypeptides and il-22 fc fusion proteins and methods of use
EP3318269B1 (en) Use of an angiopoietin-like 4 (angptl4) polypeptide in the manufacture of a medicament for the treatment of proteinuria.
US9475850B2 (en) Methods for treatment of nephrotic syndrome and related conditions
US11866468B2 (en) Methods for treatment of nephrotic syndrome and related conditions
EP2970416B1 (en) Methods for treatment of nephrotic syndrome and related conditions
KR20180009382A (ko) 치료 방법
JP2009502208A (ja) エネルギーホメオスタシスに関係する新規ペプチド
HK1220213B (en) Methods for treatment of nephrotic syndrome and related conditions
HK1252916B (en) Use of an angiopoietin-like 4 (angptl4) polypeptide in the manufacture of a medicament for the treatment of proteinuria.
US20260124275A1 (en) Methods of treating diabetes and related complications

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C41 Transfer of patent application or patent right or utility model
TA01 Transfer of patent application right

Effective date of registration: 20161108

Address after: Illinois State

Applicant after: Suman S Chugh.

Address before: alabama

Applicant before: The UAB Research Foundation

WD01 Invention patent application deemed withdrawn after publication
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20160106